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Abstract 
We report 570 carbapenemase-producing Klebsiella pneumoniae (CPKP) clinical isolates in a 1,040-bed 
Greek tertiary hospital during 2004 to 2010. The first CPKP (VIM-producing) was isolated in September 
2004. Despite initial containment, VIM producers have become endemic since 2006. KPC-producing K. 
pneumoniae was first isolated in August 2007 from a patient who came from Israel, spread rapidly, and 
outcompeted VIM. Overall, 267 (47%) VIM-producing and 301 (53%) KPC-producing strains were isolated, 
including 141 (24.7%) from patients with bacteraemia. Two isolates carrying both VIM and KPC were 
isolated in two consecutive months in 2009, but not since. The prevalence of CPKP increased from 0% in 
2003 to 38.3% in 2010 (p 
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We report 570 carbapenemase-producing Klebsiella 
pneumoniae (CPKP) clinical isolates in a 1,040-bed 
Greek tertiary hospital during 2004 to 2010. The first 
CPKP (VIM-producing) was isolated in September 
2004. Despite initial containment, VIM producers 
have become endemic since 2006. KPC-producing 
K. pneumoniae was first isolated in August 2007 from 
a patient who came from Israel, spread rapidly, and 
outcompeted VIM. Overall, 267 (47%) VIM-producing 
and 301 (53%) KPC-producing strains were isolated, 
including 141 (24.7%) from patients with bacteraemia. 
Two isolates carrying both VIM and KPC were isolated 
in two consecutive months in 2009, but not since. 
The prevalence of CPKP increased from 0% in 2003 
to 38.3% in 2010 (p<0.0001). All genotyped KPC pro-
ducers harboured blaKPC-2 and belonged to two clones, 
among which the hyperepidemic Greek clone, related 
to those from the United States and Israel, predomi-
nated. Most metallo-beta-lactamase (MBL) produc-
ers carried the blaVIM-1 gene and belonged to several 
clones, whereas all but one isolate with blaVIM-12 were 
clustered within a five-month period, arising from one 
clone. Resistance to non-beta-lactam antibiotics was 
also increased among CPKP. They were almost invari-
ably resistant to ciprofloxacin and trimethoprim-sul-
famethoxazole. Resistance to colistin increased from 
3.5% (4/115) in 2008 to 20.8% (25/120) in 2010, and 
resistance to tigecycline also increased. Following 
reinforcement of infection control measures, preva-
lence of CPKP (mainly KPC) has been reduced since 
mid-2009 (from 46% in 2009 to 38.3% in 2010). In view 
of the exhaustion of available therapies, investment in 
infection control resources and optimal antibiotic use 
is urgently required.
Introduction
Carbapenems are important therapeutic agents for 
treating infections caused by multi-drug resistant 
Gram-negative bacteria. Their efficacy, however, is 
threatened by the emergence of resistant isolates. In 
Greece (and elsewhere in Europe) a common mechanism 
is acquisition of hydrolytic enzymes (carbapenemases) 
inactivating beta-lactams [1,2]. The genes encoding 
carbapenemases are located on mobile genetic ele-
ments, allowing them to spread. Other mechanisms of 
resistance to carbapenems include the combination of 
extended spectrum beta-lactamase (ESBL) production 
with porin changes and/or upregulated efflux pumps 
(the latter particularly common among carbapenem-
resistant Pseudomonas aeruginosa) [3,4].
Carbapenemases were initially found in non-ferment-
ing bacteria; however, among Enterobacteriaceae, 
Klebsiella pneumoniae strains carrying acquired car-
bapenemases are increasingly reported [5]. The most 
prevalent carbapenemases are the molecular class B 
metallo-beta-lactamases (MBLs), mainly of VIM- and 
IMP-type, and the (class A) K. pneumoniae-carbapene-
mases (KPCs) [5]. More recently, outbreaks have been 
described of K.  pneumoniae carrying the carbapen-
emases OXA-48 (Ambler class D) [6] and the New Delhi 
MBL (NDM-1) [7]. Carbapenemase-producing K.  pneu-
moniae (CPKP) have been isolated worldwide, includ-
ing most European countries [8]; CPKP are nowadays 
endemic in Greece (both VIM and KPC) and Israel (KPC). 
The presence of KPC in Israel was first reported in 2005 
[9] and in Greece in 2007 [10].
Hippokration is a 1,040-bed, tertiary-care hospital in 
northern Greece, with all medical, surgical and pae-
diatric subspecialties, a solid-organ transplantation 
unit and four intensive care units. The first CPKP in 
Hippokration Hospital was isolated in September 2004. 
Herein, we describe a seven-year study of the microbio-
logical and molecular characteristics of K. pneumoniae 
producing different MBL- and KPC-type carbapene-
mases, endemic in this institution since 2006.
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Methods
Between September 2004 and December 2010, we col-
lected all K.  pneumoniae isolates from clinical speci-
mens (one per patient) that had a minimum inhibitory 
concentration (MIC) of >1 mg/L imipenem and stored 
them at -74 °C in 1% proteose-peptone containing 7% 
glycerol for further evaluation. Bacterial identifica-
tion to species level and initial antibiotic susceptibil-
ity testing were performed with the VITEK2–automated 
system (bioMérieux, Marcy l’Etoile, France). Isolates 
were tested for tigecycline and colistin using the 
Etest (AB Biodisk, Solna, Sweden). For tigecycline, the 
breakpoints recommended by the United States Food 
and Drug Administration were used (susceptible: MIC 
≤2 mg/L; resistant: MIC ≥8 mg/L). For colistin, the 
breakpoints recommended by the Clinical Laboratory 
Standards Institute (CLSI) for Acinetobacter spp. were 
used (susceptible: MIC ≤2 mg/L; resistant: MIC ≥4 
mg/L) because there are no established CLSI MIC 
breakpoints against colistin for Enterobacteriaceae. 
All isolates were phenotypically screened for MBL- 
and KPC-type carbapenemases, using the imipenem/
EDTA double-disk synergy test [11] and the imipenem/
boronic acid combined-disc test [12], respectively.
Following phenotypic identification, MBL- and KPC-
producing isolates were grouped according to their 
susceptibility profile (data not shown). However, no 
clear relationship between specific susceptibility pro-
files and clones could be identified with certainty. We 
selected 152 strains randomly (one of four) from each 
group, spanning all study years, for PCR amplification 
and sequencing, using primers specific for blaVIM, blaIMP 
and blaKPC, as previously described [13,14]. The MICs of 
imipenem, meropenem and ertapenem for those 152 
isolates were confirmed with the CLSI broth microdilu-
tion method [15], using Escherichia coli ATCC 25922 as 
control. The relatedness of isolates was determined by 
enterobacterial repetitive intergenic consensus (ERIC) 
PCR using the primer ERIC-2 [16].
Results
During the study period, 570 CPKP were isolated from 
clinical samples: blood (n=141; 24.7%), urine (n=166; 
29.1%), surgical wounds (n=94; 16.5%), bronchial aspi-
rates (n=35; 6.2%), central venous catheter tips (n=44; 
7.7%), drainage sites (n=43; 7.5%), abscesses (n=17; 
3.0%) and other sites (n=30; 5.3%, including cerebro-
spinal fluid, pleural or peritoneal tap, etc).
CPKP were isolated in all departments and 46.1% of 
isolates derived from two units: the eight-bed inten-
sive care unit (ICU) (154 isolates; 27.0%) and the 10-bed 
organ transplant unit (109 isolates; 19.1%). The remain-
ing CPKP were isolated in the hospital’s surgical wards 
(146 isolates; 25.6%), the medical wards (139 isolates; 
24.4%) and the paediatric/neonatal wards (22 isolates; 
3.9%). The overall prevalence of CPKP among K. pneu-
moniae in the hospital increased from 0% in 2003 to 
38.3% in 2010 (p<0.0001).
VIM-producing Klebsiella pneumoniae
In our hospital, the first CPKP was isolated in 
September 2004 from an infected wound of a patient 
who had been transferred from the ICU to the ortho-
pedic ward; The MIC of imipenem and meropenem 
were 4 and 2 mg/L, respectively. Phenotypic testing 
revealed synergy between imipenem and EDTA, and 
the presence of the blaVIM-1 gene was identified. A fur-
ther seven VIM-1 producing CPKP were isolated in the 
following three months: four in the ICU, two in surgi-
cal ward and one in the transplantation unit. Following 
rigorous infection control measures, the outbreak tem-
porarily ceased, and only five sporadic cases occurred 
over the following 14 months. A new wave started in 
March 2006; since then CPKP have been endemic in the 
hospital. The outbreak trend is depicted in Figure 1.
KPC-producing Klebsiella pneumoniae
In August 2007, a K.  pneumoniae isolate resistant to 
imipenem (MIC>16 mg/L) was recovered from a central 
venous catheter tip of a Dutch tourist, who was admit-
ted to the ICU of our hospital after a stay in Israel. 
Unlike the previous CPKP isolates, the isolate from 
this patient was negative in the imipenem-EDTA test. 
This strain was resistant to aztreonam, and synergy 
was demonstrated between amoxicillin/clavulanic acid 
and cefotaxime. A positive imipenem/boronic acid test 
suggested the presence of KPC, which was confirmed 
by blaKPC sequencing. KPC-producing organisms were 
initially confined to the ICU and organ transplant unit. 
In October 2007, they were isolated in surgical wards 
(orthopedic) and later in the same month in medical 
wards (renal, neurology).
KPC spread rapidly in the hospital, becoming increas-
ingly prevalent (from 21 isolates in 2007 to 134 in 
2009), while VIM-producing isolates declined (from 77 
isolates in 2007 to 25 in 2009) (Table 1).
Since mid-2009, the prevalence of KPC isolates has 
been gradually declining, whereas the much lower rate 
of VIM producers has slightly increased (Figure 2). In 
May and June 2009, two (to date unique) isolates were 
identified that carried both blaKPC and blaVIM [17]. Table 
2 summarises the CPKP isolated in the different wards/
departments of the hospital over the study period.
Phenotypic and genotypic analysis of isolates
Overall, 267 (47%) isolates were phenotypically char-
acterised as MBL- and 301 (53%) as KPC-producing 
(Table 1). All 70 genotypically tested KPC producers har-
boured the blaKPC-2 gene. Among MBL producers, molec-
ular analysis revealed the presence of 72 blaVIM-1 and 
10 blaVIM-12 genes. The latter were clustered between 
November 2006 and April 2007, with the exception of 
one sporadic case in June 2007. ERIC analysis revealed 
several different patterns among VIM producers, 
including a distinct clone comprising all VIM-12 carry-
ing strains. KPC producers belonged to two different 
clones, one being predominant (data not shown).
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Resistance to imipenem and meropenem, as well as of 
MBL producers to ertapenem, was variable (MIC rang-
ing from 2 to >32 mg/L). KPC producers had invariably 
a MIC of >32 mg/L to ertapenem. Notably, 87 (32.6%) 
VIM-producing isolates were resistant to aztreonam 
(an antibiotic stable to the hydrolytic activity of MBLs). 
PCR analysis revealed that these 87 isolates also con-
tained an extended-spectrum beta-lactamase (ESBL) 
gene, blaSHV-12 or blaSHV-5.
Antimicrobial susceptibilities to non-beta-lactam 
agents are reported in Table 3. Almost all CPKP iso-
lates were resistant to ciprofloxacin and trimethoprim-
sulfamethoxazole. Gentamicin was more active than 
amikacin in vitro, particularly among KPC producers. 
Of note, 18.6% (56/301) of KPC-producing isolates were 
also resistant to colistin. Among CPKP, colistin resist-
ance increased from 3.5% (4/115) in 2008 to 20.8% 
(25/120) in 2010. Tigecycline resistance, although less 
frequent than colistin, also increased among KPC pro-
ducers (Table 3).
Discussion and conclusion
This study describes the, to our knowledge, largest 
outbreak of CPKP in a healthcare institution. As only 
clinical specimens from unique patients were included, 
and the MIC threshold for carbapenemase testing (imi-
penem >1 mg/L) was higher than the subsequently 
defined epidemiological cut-off values [18], it is possi-
ble that the prevalence of CPKP was underestimated. 
We observed on the one hand the dynamic co-existence 
of VIM- and KPC-producing strains, where KPC produc-
ers outcompeted pre-existing VIM producers, and on 
the other hand the rare emergence of strains co-pro-
ducing VIM and KPC appearing late in this epidemic.
ERIC results suggest both clonal expansion and 
horizontal transmission of resistance determinants. 
Although all early VIM-1 producing isolates belonged 
to the same clone [14], subsequent VIM producers 
belonged to multiple distinct clones; multi-clonality 
of VIM-producing CPKP circulating in Greek hospitals 
was supported by previous reports [19]. All KPC pro-
ducers belonged to two clones, the predominant of 
which likely corresponded to the hyperepidemic Greek 
clone, related to those from the United States and 
Israel; this has also been shown previously for some 
of our samples, using pulsed-field gel electrophoresis 
(PFGE) [13]. Notably, our index KPC strain was isolated 
from a patient who had been to Israel. To the best of 
Figure 1
Clinical isolates of Klebsiella pneumoniae producing VIM or KPC, in Hippokration hospital, Thessaloniki, Greece, 
September 2004–December 2010 (n=570) 
KPC: Klebsiella pneumoniae carbapenemase; VIM: Verona integron-encoded metallo-beta-lactamase.































































































































































our knowledge, this is the first report of a documented 
transfer of KPC from Israel to Greece. Remarkably, the 
timing of this transfer coincided with the peak of the 
KPC outbreak in Israel [20]. These data are in accord-
ance with previous findings on the similarities of KPC-
producing clones reported from those two countries 
in 2007 [13]. It should be noted that KPC-2 strains had 
been reported from another area in Greece (Crete) ear-
lier in the same year [21], but the origin of those iso-
lates was unknown.
Standard infection control measures (including contact 
precautions) were implemented at the beginning of the 
outbreak in Hippokration hospital. However, adher-
ence to the measures seemed to subside after the first 
months and CPKP were transmitted more widely. The 
highest incidence of CPKP was monitored in 2009, 
and since then infection control policy has been re-
assessed and intensified by the infection control com-
mittee (infectious disease physicians, the head of the 
microbiology department, infection control nurses and 
physicians from other hospital departments) according 
to guidelines from the Centers for Disease Control and 
Prevention [22].
The number of hospital infection control nurses was 
increased from one to three, and they actively moni-
tored adherence and effectiveness of intensified inter-
ventions under the guidance of an infectious disease 
physician. Staffing levels in all hospital departments, 
including the ICUs, were reassessed. Moreover, the 
accurate identification of CPKP was verified and the 
presence of carbapenemase-producing bacteria was 
communicated in written reports to all physicians. 
Affected areas received quality visits from infection 
Table 1
Klebsiella pneumoniae isolates carrying VIM and/or KPC 
in Hippokration hospital, Thessaloniki, Greece, September 
2004–December 2010 (n=570)
Year All CPKP 
VIM 
(% of all CPKP that year)
KPC 
(% of all CPKP that year)
2004 8 8 0
2005 4 4 0
2006 55 55 0
2007 98 77 (78.6) 21 (21.4)
2008 116 55 (47.4) 61 (52.6)
2009 161a 25 (15.7) 134 (84.3)
2010 128 43 (33.6) 85 (66.4)
Total 570a 267 (47.0) 301 (53.0)
CPKP: Carbapenemase-producing Klebsiella pneumoniae; KPC: 
Klebsiella pneumoniae carbapenemase; VIM: Verona integron-
encoded metallo-beta-lactamase.
a Two strains producing both VIM and KPC were isolated in 2009 
and are not included in the columns of VIM- and KPC-expressing 
isolates.
Figure 2
VIM- and KPC-producing Klebsiella pneumoniae isolates, Hippokration hospital, Thessaloniki, Greece, September 2004–
December 2010 (n=568) 
KPC: Klebsiella pneumoniae carbapenemase; VIM: Verona integron-encoded metallo-beta-lactamase.






























control nurses. Feedback from those visits,as well as 
resistance rates were communicated to the infectious 
disease physicians. Due to the endemic situation only 
infections with CPKP were monitored and no active 
surveillance took place. A database of all patients with 
CPKP was generated and distributed to the microbiol-
ogy department, infection control nurses and infec-
tious disease physicians. Incidence rates of CPKP were 
reported weekly to all hospital departments as well as 
the hospital’s administration. Patients’ location and 
transfer between departments and/or hospitals were 
monitored daily. Infection control precautions to pre-
vent patient-to-patient transmission were intensified 
and targeted patients with CPKP. Contact precautions 
were put in place for all patients with a positive CPKP 
test: Where feasible, a single patient room was used 
for isolation. However, cohorting of patients was also 
used in departments where single patient rooms were 
not available (including all ICUs). Environmental meas-
ures were also implemented including dedicated use 
of non-critical equipment. Surface cleaning and disin-
fection was reinforced as well as final cleaning after a 
patient was moved from a department.
In February 2009, the infection control committee 
and hospital administration decided not to accept 
new admissions to adult ICU for 10 days. Education 
of healthcare personnel was intensified using audits, 
posters and video presentations about hand hygiene, 
contact precautions and severity of infections due to 
CPKP. Judicious use of antimicrobials was encouraged 
and daily quality rounds and audits of antimicrobial 
prescriptions were implemented. An antimicrobial 
restriction policy was in place and all antimicrobi-
als with extended spectrum (especially carbapenems) 
were closely monitored by an infectious disease physi-
cian in cooperation with the hospital’s pharmacy. Given 
the magnitude of the problem in Greece, ‘Procrustes’, a 
nationwide action plan for the containment of carbap-
enem-resistant bacteria has been implemented as of 
November 2010; its main features have been outlined 
elsewhere [2]. With these measures in place, a reduc-
tion in the prevalence of CPKP in the hospital was 
recorded (from 46% of K. pneumoniae strains isolated 
in 2009 to 38.3% in 2010, see Figures 1 and 2).
Not surprisingly [1], this outbreak has as yet not been 
contained, despite hospital-wide reinforcement of 
infection control measures. It is likely that its appear-
ance and perpetuation had multiple contributors. Those 
included breaches in infection control practice, like low 
compliance with hand hygiene [23] and contact precau-
tions. Inter-hospital transfer of carriers is favoured in 
Greek hospitals because there is no integrated record-
ing system of re-admission alerts and inter-hospital 
communication [1]. Antibiotic overuse is an important 
contributor for the emergence and spread of resist-
ance; association between carbapenem consump-
tion and resistance has been previously documented 
[24]. As per institutional policy, in departments with a 
Table 2
Carbapenemase-producing Klebsiella pneumoniae by unit/ward, Hippokration hospital, Thessaloniki, Greece, September 
2004–December 2010 (n=570)
Year Intensive care unit (%) Transplant unit (%) Medical wards (%) Surgical wards (%) Paediatric wards (%) Total
2004 4 1 0 3 0 8 
2005 1 1 1 1 0 4
2006 27 (49.1) 7 (12.7) 9 (16.4) 10 (18.2) 2 (3.6) 55
2007 25 (25.5) 23 (23.5) 21 (21.4) 26 (26.5) 3 (3.1) 98
2008 35 (30.2) 23 (19.8) 30 (25.9) 23 (19.8) 5 (4.3) 116
2009 39 (24.2) 28 (17.4) 42 (26.1) 46 (28.6) 6 (3.7) 161
2010 23 (18.0) 26 (20.3) 36 (28.1) 37 (28.9) 6 (4.7) 128 
Total 154 (27.0) 109 (19.1) 139 (24.4) 146 (25.6) 22 (3.9) 570
Table 3
Susceptibility profile of carbapenem-resistant Klebsiella pneumoniae isolates to non-beta-lactam antimicrobial agents in 
Hippokration hospital, Thessaloniki, Greece, September 2004–December 2010 (n=568)
K. pneumoniae
(no of isolates)
 Number (%) resistant
GEN AMK CST TGC CIP SXT
VIM producers (n=267)  63 (23.6) 79 (29.6) 9 (3.4) 14 (5.2) 257 (96.3) 264 (98.9)
KPC producers (n=301) 44 (14.6) 223 (74.0) 56 (18.6) 34 (11.3) 295 (98.0) 274 (91.0)
AMK: amikacin; CIP: ciprofloxacin; CST: colistin; GEN: gentamicin; KPC: Klebsiella pneumoniae carbapenemas; SXT: trimethoprim-
sulfamethoxazole; TGC: tigecycline; VIM: Verona integron-encoded metallo-beta-lactamase.
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high prevalence of CPKP, i.e. the ICU, colistin and gen-
tamicin are used as initial empirical treatment when an 
infection with such an organism is suspected [25].
Notably, we observed different resistant profiles within 
clones in this study. Reasons for this may include the 
presence of additional mechanisms contributing to 
resistance patterns (typically, the frequent co-exist-
ence of an ESBL-type enzyme and VIM), the concurrent 
existence of several clones of VIM-producing strains, 
but also the increased rates of non-susceptibility to 
tigecycline and/or colistin, probably as a result of 
increasing use of those antibiotics for the treatment 
of infections with carbapenem-resistant organisms. 
Of particular concern are our results showing frequent 
aztreonam resistance among VIM producers, due to 
the additional carriage of an ESBL, as well as the high 
rates of resistance to non-beta-lactam agents, particu-
larly among KPC producers. In agreement with recent 
reports [26, 27], increasing colistin resistance under-
lines a real threat from the emergence of multi- or 
pandrug-resistant bacteria. In view of the exhaustion 
of available therapeutic options, investment in infec-
tion control resources and optimal antibiotic use, along 
with co-ordinated efforts from all involved parties is 
urgently required.
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